BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 17229495)

  • 1. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.
    Pittman PR; Leitman SF; Oro JG; Norris SL; Marano NM; Ranadive MV; Sink BS; McKee KT
    Clin Diagn Lab Immunol; 2005 Jun; 12(6):713-21. PubMed ID: 15939745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.
    Singer DE; Schneerson R; Bautista CT; Rubertone MV; Robbins JB; Taylor DN
    Vaccine; 2008 Feb; 26(7):869-73. PubMed ID: 18206278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
    Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
    Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.
    Klinman DM; Currie D; Lee G; Grippe V; Merkel T
    Microbes Infect; 2007 Oct; 9(12-13):1478-83. PubMed ID: 17913545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats.
    Ndumnego OC; Crafford J; Beyer W; van Heerden H
    BMC Vet Res; 2013 Dec; 9():265. PubMed ID: 24373579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.
    Aulinger BA; Roehrl MH; Mekalanos JJ; Collier RJ; Wang JY
    Infect Immun; 2005 Jun; 73(6):3408-14. PubMed ID: 15908368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
    Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
    Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.
    Rao VV; Godin CS; Lacy MJ; Inglefield JR; Park S; Blauth B; Reece JJ; Ionin B; Savransky V
    Int J Toxicol; 2021 Oct; 40(5):442-452. PubMed ID: 34281421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.
    Sawada-Hirai R; Jiang I; Wang F; Sun SM; Nedellec R; Ruther P; Alvarez A; Millis D; Morrow PR; Kang AS
    J Immune Based Ther Vaccines; 2004 May; 2(1):5. PubMed ID: 15140257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
    Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
    PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.
    Davis CW; Jackson KJL; McElroy AK; Halfmann P; Huang J; Chennareddy C; Piper AE; Leung Y; AlbariƱo CG; Crozier I; Ellebedy AH; Sidney J; Sette A; Yu T; Nielsen SCA; Goff AJ; Spiropoulou CF; Saphire EO; Cavet G; Kawaoka Y; Mehta AK; Glass PJ; Boyd SD; Ahmed R
    Cell; 2019 May; 177(6):1566-1582.e17. PubMed ID: 31104840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.
    Quinn CP; Sabourin CL; Schiffer JM; Niemuth NA; Semenova VA; Li H; Rudge TL; Brys AM; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Parker SD; Babcock J; Keitel W; Poland GA; Keyserling HL; El Sahly H; Jacobson RM; Marano N; Plikaytis BD; Wright JG
    Clin Vaccine Immunol; 2016 Apr; 23(4):326-38. PubMed ID: 26865594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.
    Oscherwitz J; Yu F; Cease KB
    Infect Immun; 2009 Dec; 77(12):5509-18. PubMed ID: 19805525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.
    Galen JE; Chinchilla M; Pasetti MF; Wang JY; Zhao L; Arciniega-Martinez I; Silverman DJ; Levine MM
    J Infect Dis; 2009 Feb; 199(3):326-35. PubMed ID: 19099487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
    Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
    Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
    Pittman PR; Norris SL; Barrera Oro JG; Bedwell D; Cannon TL; McKee KT
    Vaccine; 2006 Apr; 24(17):3654-60. PubMed ID: 16497418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.
    Semenova VA; Steward-Clark E; Stamey KL; Taylor TH; Schmidt DS; Martin SK; Marano N; Quinn CP
    Clin Diagn Lab Immunol; 2004 Sep; 11(5):919-23. PubMed ID: 15358653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for improved anthrax vaccines.
    Brey RN
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1266-92. PubMed ID: 15935874
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.